Homocysteine, Alzheimer genes and proteins, and measures of cognition and depression in older men

Journal of Alzheimer's Disease

Volumn 6, Issue 3, 2004, Pages 329-336

  Flickera, Leon ^a,e   Martins, R N ^b,c,d   Thomas, J ^a   Acres, J ^a,b   Taddei, K ^b,c,d   Norman, P ^b   Jamrozik, K ^b   Almeida, O P ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Amyloid protein; Apolipoprotein E; Cognition; Dementia; Depression; Geriatric; Homocysteine; Methylnetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN E4; HOMOCYSTEINE; PROTEIN; UNCLASSIFIED DRUG;

AGED; AGING; ALLELE; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; CLOCK DRAWING TEST; COGNITION; CORRELATION ANALYSIS; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; GENE MUTATION; GENOTYPE; GERIATRIC DEPRESSION SCALE 15; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RATING SCALE;

EID: 3042529598     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2004-6313     Document Type: Article

References (43)

1. O.P. Almeida and S.A. Almeida, Short versions of the Geriatric Depression, Int J Geriatr Psych 14 (1999), 858-865.
2. O.P. Almeida, L. Flicker, N.T. Lautenschlager, P. Leedman, S. Vasikaran and F. van Bockxmeer, Contribution of the MTHFR gene to the causal pathway for depression and cognitive impairment in later life, Neurobiol Aging, in press.
3. Anonymous, Apolipoprotein E genotyping in Alzheimer's disease, Lancet 347 (1996), 1091-1095.
4. A. Beck, N. Epstein, G. Brown and R. Steer, An inventory for measuring clinical anxiety, J Consult Clin Psychol 56 (1988), 893-897.
5. J. Beilby and E. Rossi, Homocysteine and disease, Pathology 32 (2000), 262-273.
6. T.F. Bottiglieri, Vitamin B12 and Neuropsychiatric Disorders Nutrition Reviews 54 (1996), 382-390.
7. A.A. Boyt, K. Taddei, J. Hallmeyer, E. Helmerhorst, S.E. Gandy, S. Craft and R.N. Martins, The effect of insulin and glucose on the plasma concentrations of Alzheimer's amyloid precursor protein, Neuroscience 95 (2000), 727-734.
8. L. Brattstrom, D.E. Wilcken, J. Ohrvik and L. Brudin, Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis, Circulation 98 (1998), 2520-2526.
9. M.J. Bullido, M.J. Artiga, M. Recuero, I. Sastre, M.A. Garcia, J. Aldudo, C. Lendon, S.W. Han, J.C. Morris, A. Frank, J. Vazquez, A. Goate and F. Valdivieso, A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia, Nat Genet 18 (1998), 69-71.
10. A.I. Bush, S. Whyte, L.D. Thomas, T.G. Williamson, C.J. Van Tiggelen, J. Currie, D.H. Small, R.D. Moir, Q.X. Li, B. Rumble and C.L. Masters, An abnormality of plasma amyloid protein precursor in Alzheimer's disease, Ann Neurology 32 (1992), 57-65.
11. J.L. Cummings and G. Cole, Alzheimer disease, JAMA 287 (2002), 2335-2338.
12. D.C. Delis, J.H. Kramer, E. Kaplan and B.A. Ober, CVLT-II California Verbal Learning Test Second Edition Adult Version, The Psychological Corporation (1999).
13. T. Den Heijer, S.E. Vermeer, R. Clarke, M. Oudkerk, P.J. Koudstaal, A. Hofman and M.M.B. Breteler, Homocysteine and brain atrophy on MRI of non-demented elderly, Brain 126 (2003), 170-175.
14. M.R. Eastwood, S.L. Rifat, H. Nobbs and J. Ruderman, Mood disorder following cerebrovascular accident, Br J Psych 154 (1989), 195-200.
15. J.E. Graham, K. Rockwood, B.L. Beattie, R. Eastwood, S. Gauthier, H. Tuokko and I. McDowell, Prevalence and severity of cognitive impairment with and without dementia in an elderly population, Lancet 349 (1997), 1793-1796.
16. G.J. Hankey and J.W. Eikelboom, Homocysteine and vascular disease, Lancet 354 (1999), 407-413.
17. J.E. Hixson and D.T. Vernier, Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI, J. Lipid Res. 31 (1990), 545-548.
18. P.I. Ho, S.C. Collins, S. Dhitavat, D. Ortiz, D. Ashline, E. Rogers and T.B. Shea, Homocysteine potentiates β-amyloid neurotoxicity: role of oxidative stress, Journal of Neurochemistry 78 (2001), 249-253.
19. K. Jamrozik, P.E. Norman, C.A. Spencer, R.W. Parsons, R. Tuohy, M.M. Lawrence-Brown and J.A. Dickinson, Screening for abdominal aortic aneurysm: lessons from a population-based study, Medical Journal of Australia 173 (2000), 345-350.
20. J. Johnson, M.M. Weissman and G.L. Klerman, Service utilization and social morbidity associated with depressive symptoms in the community, JAMA 267 (1992), 1478-1483.
21. J. Kang, H. Lemaire, A. Unterbeck, J.M. Salbaum, C.L. Masters, K. Grzeschik, G. Multhaup, K. Beyreuther, B. Muller-Hill, The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature 325 (1985), 733-736.
22. I.I. Kruman, T.S. Kumaravel, A. Iohani, W.A. Pedersen, R.G. Cutler, Y. Kruman, N. Haughey, J. Lee, M. Evans and M.P. Mattson, Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease, Journal of Neuroscience 22 (2002), 1752-1762.
23. S.M. Laws, E. Hone, S. Gandy and R.N. Martins, Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription, Journal of Neurochemistry 84 (2003), 1215-1236.
24. A. Leino, Fully automated measurement of total homocysteine in plasma and serum on the Abbott Imx analyzer, Clin Chem 1999(45) (1999), 569-571.
25. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers and D. Roth, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation, Modification of Diet in Renal Disease Study Group Ann Intern Med 130 (1999), 461-470.
26. R.N. Martins, J. Muir, W.S. Brooks, H. Creasey, P. Montgomery, P. Sellers and G.A. Broe, Plasma amyloid precursor is decreased in Alzheimer's disease, Neuroreport 4 (1993), 757-759.
27. C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald and K. Beyreuther, Amyloid plaque core protein in Alzheimer's Disease and Down syndrome, Proc. Natl. Acad. Sci. USA. 82 (1985), 4245-4249.
28. P.D. Mehta, T. Pirtilla, S.P. Mehta, E.A. Sersen and P.S. Aisen, Wisniewski HM Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease, Arch Neurol 57 (2000), 100-105.
29. S.S. Mok, B.J. Turner, K. Beyreuther, C.L. Masters, C.J. Barrow and D.H. Small, Toxicity of substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by homocysteine, Eur J Biochem 269 (2002), 3014-3022.
30. D.W. Molloy, E. Alemayehu and R. Roberts, Reliability of a Standardized Mini-Mental State Examination compared with the traditional, Mini-Mental State Examination Am J Psych 148 (1991), 102-105.
31. J. O'Brien, D. Ames, E. Chiu, I. Schweitzer, P. Desmond and B. Tress, Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study, BMJ 317 (1998), 982-984.
32. W.G. Rosen, R.C. Mohs and K.L. Davis, A new rating scale for Alzheimer's disease, Am J Psych 141 (1984), 1356-1364.
33. P.S. Sachdev, M. Valenzuela, X.L. Wang, J.C. Looi and H. Brodaty, Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals, Neurology 58 (2002), 1539-1541.
34. K. Schulman, R. Shedletsky and I. Silver, The challenge of time. Clock drawing and cognitive function in the elderly, Int Journal Geriatr Psych 1 (1986), 135-140.
35. S.M. Sell and P.R. Lugemwa, Development of a highly rapid PCR-RFLP genotyping assay for the methylenetetrahydrofolate reductase gene, Genet. Test. 3 (1999), 287-289.
36. S. Seshadri, A. Beiser, J. Selhub, P.F. Jaques, I.H. Rosenberg, R.B. D'Agostino, P.W.F. Wilson and P.A. Wolf, Plasma homocysteine as a risk factor for dementia and Alzheimer's disease, N Engl J Med 346 (2002), 476-483.
37. D.A. Snowdon, L.H. Greiner, J.A. Mortimer, K.P. Riley, P.A. Greiner and W.R. Markesbery, Brain infarction and the clinical expression of Alzheimer disease: the Nun Study, JAMA 277 (1997), 813-817.
38. K. Taddei, R. Clarnette, S.E. Gandy and R.N. Martins, Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease, Neurosci. Lett. 223 (1997), 29-32.
39. C.E. Teunissen, J. de Vente, H.W.M. Steinbusch and C. De Bruijn, Biochemical markers related to Azheimer's dementia in serum and cerebrospinal fluid, Neurobiology of Aging 23 (2002), 485-508.
40. M. Van Der Weyden, The burden of disease and injury in Australia: time for action, Med J Aust 171 (1999), 581-582.
41. L.M. Waite, G.A. Broe and H. Creasey et al., Neurodegenerative and other chronic disorders among people, Med J Aust 167 (1997), 429-432.
42. J.E. Ware Jr and B. Gandek, Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project, J Clin Epidemiol 51 (1998), 903-912.
43. A.R. White, X. Huang, M.F. Jobling, C.J. Barrow, K. Beyreuther, C.L. Masters, A.I. Bush and R. Cappai, Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in Alzheimer's-type neurodegenerative pathways, Journal of Neurochemistry 76 (2001), 1509-1520.